Peter Brossart

This study shows that NLRP3 inflammasome activation drives JAK2V617F mutant myeloproliferative neoplasms by promoting inflammation, platelet production, and fibrosis, and that its inhibition can reverse disease features.

This study shows that the CCR4/CCL17 axis promotes intestinal acute GvHD by recruiting T cells and increasing Gata3 expression, and identifies ruxolitinib as a potential therapeutic.